Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

prostatectomy
chronic obstructive pulmonary disease
urinary tract infection
abiraterone
docetaxel
  • 2 views
  • 19 Feb, 2024
  • 16 locations
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial (FUMS-EDJS2024)

This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer:Does this combination improve the 2-year recurrence-free survival …

  • 0 views
  • 14 Jun, 2025
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

refractory multiple myeloma
flow cytometry
bcma
oxygen saturation
ejection fraction
  • 0 views
  • 19 Feb, 2024
  • 1 location
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

second malignancy
squamous cell carcinoma of the head and neck
measurable disease
io102
cavity
  • 0 views
  • 19 Feb, 2024
  • 1 location
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

recurrent head and neck squamous cell carcinoma
cancer of the head
metastatic head and neck squamous cell carcinoma
measurable disease
cetuximab
  • 0 views
  • 19 Feb, 2024
  • 1 location
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse events, quality of life) when treating Performance Status 2 patients with the …

non-small cell lung cancer
pemetrexed
pembrolizumab
paclitaxel
cancer treatment
  • 0 views
  • 19 Feb, 2024
  • 1 location
Combination Immunotherapy Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines …

sarcoma
serum bilirubin level
immunosuppression
renal function
kidney function tests
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum …

cisplatin
caries
metastatic head and neck squamous cell carcinoma
capecitabine
docetaxel
  • 0 views
  • 19 Feb, 2024
  • 3 locations
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

stem cell transplant
biotherapy
solid tumor
iobenguane
cytokine release syndrome
  • 0 views
  • 19 Feb, 2024
  • 1 location
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

biospecimen collection
  • 0 views
  • 19 Feb, 2024
  • 381 locations